

**All ETCTN Trials: Updated June 9, 2025 (Includes trials that are in review, approved, and active)**

<b>CTEP Trial ID</b>	<b>Title</b>	<b>Limited/ETCTN-wide</b>	<b>Radiation Oncology</b>	<b>Disease Area(s)</b>	<b>ClinicalTrials.gov website (if available)</b>
10144	A Phase II Study of Olaparib (AZD2281) in Patients with Metastatic/Advanced Urothelial Carcinoma and other genitourinary tumors with DNA-Repair Defects	ETCTN-wide	No	Genitourinary	<a href="https://clinicaltrials.gov/ct2/show/NCT03375307">https://clinicaltrials.gov/ct2/show/NCT03375307</a>
10146	Randomized phase 2 clinical trial of nab-paclitaxel + MEDI4736 (durvalumab) + tremelimumab + neoantigen vaccine vs. nab-paclitaxel + MEDI4736 (durvalumab) + tremelimumab in patients with metastatic triple negative breast cancer	ETCTN-wide	No	Breast	<a href="https://clinicaltrials.gov/ct2/show/NCT03606967">https://clinicaltrials.gov/ct2/show/NCT03606967</a>
10204	Phase Ib Study of Nivolumab in Patients with Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)	ETCTN-wide	No	Solid tumors (no specified mutations)	<a href="https://clinicaltrials.gov/ct2/show/NCT03816345">https://clinicaltrials.gov/ct2/show/NCT03816345</a>
10214	Immune Checkpoint Blockade for Kidney Transplant Recipients with Selected Unresectable or Metastatic Cancers	ETCTN-wide	No	Skin and other melanoma	<a href="https://clinicaltrials.gov/ct2/show/NCT03816332">https://clinicaltrials.gov/ct2/show/NCT03816332</a>
10273	A Phase I Study of M3814 in Combination with MEC in Patients with Relapsed or Refractory Acute Myeloid Leukemia	ETCTN-wide	No	Leukemia	<a href="https://clinicaltrials.gov/ct2/show/NCT03983824">https://clinicaltrials.gov/ct2/show/NCT03983824</a>
10276	A Phase I/II Study of M3814 and Avelumab in Combination with Hypofractionated Radiation in Patients with Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies	ETCTN-wide (in PII)	Yes	Gastrointestinal, Solid tumors (dose escalation)	<a href="https://clinicaltrials.gov/ct2/show/NCT04068194">https://clinicaltrials.gov/ct2/show/NCT04068194</a>

**All ETCTN Trials: Updated June 9, 2025 (Includes trials that are in review, approved, and active)**

<b>CTEP Trial ID</b>	<b>Title</b>	<b>Limited/ETCTN-wide</b>	<b>Radiation Oncology</b>	<b>Disease Area(s)</b>	<b>ClinicalTrials.gov website (if available)</b>
10285	Phase 1/2 Study of an EZH2 Inhibitor (Tazemetostat) in Combination with Dual BRAF/MEK Inhibition in Patients with BRAF- Mutated Metastatic Melanoma who Progressed on Prior BRAF/MEK Inhibitor Therapy	ETCTN-wide	No	Skin and other melanoma	<a href="https://clinicaltrials.gov/ct2/show/NCT04557956?id=10285">https://clinicaltrials.gov/ct2/show/NCT04557956?id=10285</a>
10292	DURVA+ : Evaluation of the Safety and Pharmacodynamics of Anti-PD-L1 Antibody MEDI4736 (Durvalumab) in Combination with Chemotherapy in Patients with Advanced Solid Tumors	ETCTN-wide	No	Solid tumors (no specified mutations)	<a href="https://clinicaltrials.gov/ct2/show/NCT03907475">https://clinicaltrials.gov/ct2/show/NCT03907475</a>
10299	A Phase I Study to Investigate the Safety of the Ubiquitin Activating Enzyme Inhibitor TAK-243 in Adult Solid Tumor and Lymphoma Patients	ETCTN-wide	No	Lymphoma, Solid tumors (no specified mutations)	<a href="https://clinicaltrials.gov/study/NCT06223542">https://clinicaltrials.gov/study/NCT06223542</a>
10301	A Phase I and Randomized Phase II Trial of Radium-223 Dichloride, M3814, & Avelumab in Advanced Metastatic Castrate-Resistant Prostate Cancer (mCRPC)	ETCTN-wide	Yes	Genitourinary	<a href="https://clinicaltrials.gov/ct2/show/NCT04071236">https://clinicaltrials.gov/ct2/show/NCT04071236</a>
10335	A Phase 1 Study of Lenalidomide in Combination with EPOCH Chemotherapy for HTLV-Associated Adult T-Cell Leukemia-Lymphoma (ATLL)	ETCTN-wide	No	Leukemia, Lymphoma	<a href="https://clinicaltrials.gov/ct2/show/NCT04301076">https://clinicaltrials.gov/ct2/show/NCT04301076</a>
10355	A Phase I Study of DS-8201a in Combination with Olaparib in HER2-Expressing Malignancies	ETCTN-wide	No	Solid tumors (mutations), solid tumor (dose escalation), gynecologic	<a href="https://clinicaltrials.gov/ct2/show/NCT04585958">https://clinicaltrials.gov/ct2/show/NCT04585958</a>

**All ETCTN Trials: Updated June 9, 2025 (Includes trials that are in review, approved, and active)**

<b>CTEP Trial ID</b>	<b>Title</b>	<b>Limited/ETCTN-wide</b>	<b>Radiation Oncology</b>	<b>Disease Area(s)</b>	<b>ClinicalTrials.gov website (if available)</b>
10358	Phase 1/1B study of DS8201a in combination with ATR Inhibition (AZD6738) in advanced solid tumors with HER2 expression (DASH Trial)	ETCTN-wide	No	Gastrointestinal, Solid tumors (dose escalation), Solid tumors (mutations)	<a href="https://clinicaltrials.gov/ct2/show/NCT04704661">https://clinicaltrials.gov/ct2/show/NCT04704661</a>
10366	A Phase 1/Randomized Phase 2 Study of M3814 (Peposertib) in Combination with Hypofractionated Radiotherapy for the Treatment of Locally Advanced Pancreatic Adenocarcinoma	ETCTN-wide	No	Gastrointestinal	<a href="https://clinicaltrials.gov/study/NCT04172532">https://clinicaltrials.gov/study/NCT04172532</a>
10371	A Pharmacodynamics-Driven Trial of Talazoparib, an Oral PARP Inhibitor, in Patients with Advanced Solid Tumors and Aberrations in Genes Involved in DNA Damage Response	ETCTN-wide	No	Solid tumors (mutations)	<a href="https://clinicaltrials.gov/ct2/show/NCT04550494">https://clinicaltrials.gov/ct2/show/NCT04550494</a>
10401	A Phase 0 window-of-opportunity pharmacodynamic trial of triapine (NSC# 663249) in uterine corpus serous adenocarcinoma	ETCTN-wide	No	Gynecologic	<a href="https://clinicaltrials.gov/ct2/show/NCT04494113">https://clinicaltrials.gov/ct2/show/NCT04494113</a>
10422	Abemaciclib and Olaparib for Recurrent Ovarian Cancer	ETCTN-wide	No	Gynecologic	<a href="https://clinicaltrials.gov/ct2/show/NCT04633239?id=10422">https://clinicaltrials.gov/ct2/show/NCT04633239?id=10422</a>
10433	Phase I/Ib trial evaluating the safety and efficacy of BET inhibitor, ZEN003694 with PD-1 inhibitor, nivolumab with or without CTLA-4 inhibitor, ipilimumab in solid tumors	ETCTN-wide	No	Solid tumors (no specified mutations), Gynecologic	<a href="https://clinicaltrials.gov/ct2/show/NCT04840589">https://clinicaltrials.gov/ct2/show/NCT04840589</a>
10440	A Phase 1/1a Study of Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for Relapsed/Refractory Light Chain Amyloidosis	ETCTN-wide	No	Myeloma	<a href="https://clinicaltrials.gov/ct2/show/NCT04847453">https://clinicaltrials.gov/ct2/show/NCT04847453</a>

**All ETCTN Trials: Updated June 9, 2025 (Includes trials that are in review, approved, and active)**

<b>CTEP Trial ID</b>	<b>Title</b>	<b>Limited/ETCTN-wide</b>	<b>Radiation Oncology</b>	<b>Disease Area(s)</b>	<b>ClinicalTrials.gov website (if available)</b>
10445	Phase I Dose Escalation and Expansion Study of Tazemetostat in Combination with Topotecan and Pembrolizumab in Recurrent Small Cell Lung Cancer	ETCTN-wide	No	Lung	<a href="https://clinicaltrials.gov/study/NCT05353439">https://clinicaltrials.gov/study/NCT05353439</a>
10466	A Phase II Study of Bevacizumab, Erlotinib and Atezolizumab in Subjects with Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) Associated or Sporadic Papillary Renal Cell Cancer	ETCTN-wide	No	Genitourinary	<a href="https://clinicaltrials.gov/ct2/show/NCT04981509">https://clinicaltrials.gov/ct2/show/NCT04981509</a>
10483	Phase Ib Trial of Erdafitinib Combined with Enfortumab Vedotin Following Platinum and PD1/L1 Inhibitors for Metastatic Urothelial Carcinoma with FGFR2/3 Genetic Alterations	ETCTN-wide	No	Genitourinary	<a href="https://clinicaltrials.gov/ct2/show/NCT04963153">https://clinicaltrials.gov/ct2/show/NCT04963153</a>
10499	Phase Ib/II Study of ZEN003694 and Entinostat in Advanced and Refractory Solid Tumors and Lymphomas	ETCTN-wide	No	Lymphoma, Solid tumors (no specified mutations)	<a href="https://clinicaltrials.gov/ct2/show/NCT05053971">https://clinicaltrials.gov/ct2/show/NCT05053971</a>
10507	A Phase 1/2 Study of the Bromodomain Inhibitor ZEN003694 in Combination with Etoposide/Platinum in Patients with NUT Carcinoma	ETCTN-wide	No	Sarcoma	<a href="https://clinicaltrials.gov/ct2/show/NCT05019716">https://clinicaltrials.gov/ct2/show/NCT05019716</a>
10490	Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 2 Talazoparib and Temozolomide	ETCTN-wide	No	Solid tumors (no specified mutations)	<a href="https://clinicaltrials.gov/ct2/show/NCT05142241">https://clinicaltrials.gov/ct2/show/NCT05142241</a>
10492	Phase I/Ib Study of AKT Inhibitor Ipatasertib with Chemoradiation for Locally Advanced Head and Neck Cancer	ETCTN-wide	Yes	Head and neck	<a href="https://clinicaltrials.gov/ct2/show/NCT05172245">https://clinicaltrials.gov/ct2/show/NCT05172245</a>

**All ETCTN Trials: Updated June 9, 2025 (Includes trials that are in review, approved, and active)**

<b>CTEP Trial ID</b>	<b>Title</b>	<b>Limited/ETCTN-wide</b>	<b>Radiation Oncology</b>	<b>Disease Area(s)</b>	<b>ClinicalTrials.gov website (if available)</b>
10486	Phase 2 Trial of the Combination of the BET Inhibitor, ZEN-3694, and the PARP Inhibitor Talazoparib, in Patients with Molecularly-Selected Solid Tumors (ComBET)	ETCTN-wide	No	Solid tumors (no specified mutations)	<a href="https://clinicaltrials.gov/ct2/show/NCT05327010">https://clinicaltrials.gov/ct2/show/NCT05327010</a>
10495	Phase I Trial of DS-8201a (Trastuzumab Deruxtecan) in Combination with Neratinib in Solid Tumors with HER2 Alterations	ETCTN-wide	No	Solid tumors (no specified mutations)	<a href="https://clinicaltrials.gov/ct2/show/NCT05372614">https://clinicaltrials.gov/ct2/show/NCT05372614</a>
10504	A Phase 2 Study of Atezolizumab with or Without Selinexor in Alveolar Soft Part Sarcoma (AXIOM)	ETCTN-wide	No	Sarcoma	<a href="https://clinicaltrials.gov/ct2/show/NCT05333458">https://clinicaltrials.gov/ct2/show/NCT05333458</a>
10508	A Phase 1 Study of Nivolumab in Combination with ASTX727 in B-cell Lymphoma (NHL or HL) with an Expansion Cohort in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) and Hodgkin lymphoma (HL)	ETCTN-wide	No	Lymphoma	<a href="https://clinicaltrials.gov/ct2/show/NCT05272384">https://clinicaltrials.gov/ct2/show/NCT05272384</a>
10449	A Phase 1 Study of ZEN003694 in Combination with Binimetinib in Solid Tumors with RAS Pathway Alterations and Triple Negative Breast Cancer	Limited (for dose escalation )	No	Breast	<a href="https://clinicaltrials.gov/ct2/show/NCT05111561">https://clinicaltrials.gov/ct2/show/NCT05111561</a>
10509	A Phase 1 Study of BET Bromodomain Inhibitor ZEN003694 in Combination with the CDK4/6 Inhibitor Abemaciclib in Patients with NUT Carcinoma and Other Solid Tumors	ETCTN-wide	No	ST escalation, Sarcoma	<a href="https://clinicaltrials.gov/ct2/show/NCT05372640">https://clinicaltrials.gov/ct2/show/NCT05372640</a>
10512	A Phase 2 Randomized Study of the BER Inhibitor TRC102 in Combination with Standard Pemetrexed-Platinum-Radiation in Stage III Non-Squamous Non-Small Cell Lung Cancer	ETCTN-wide	Yes	Lung	<a href="https://clinicaltrials.gov/ct2/show/NCT05198830">https://clinicaltrials.gov/ct2/show/NCT05198830</a>

**All ETCTN Trials: Updated June 9, 2025 (Includes trials that are in review, approved, and active)**

<b>CTEP Trial ID</b>	<b>Title</b>	<b>Limited/ETCTN-wide</b>	<b>Radiation Oncology</b>	<b>Disease Area(s)</b>	<b>ClinicalTrials.gov website (if available)</b>
10237	A Phase 1 Study of MLN7243 (TAK-243) for Either Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome/Chronic Myelomonocytic Leukemia Refractory to Hypomethylating Agents	Limited	No	Leukemia	<a href="https://clinicaltrials.gov/ct2/show/NCT03816319">https://clinicaltrials.gov/ct2/show/NCT03816319</a>
10464	A Phase 1 Study of Olaparib in Combination with Durvalumab (MEDI4736) and Concurrent Radiation Therapy Following First-Line Chemotherapy in Locally Advanced Unresectable Pancreatic Cancer	ETCTN-wide	No	Gastrointestinal	<a href="https://clinicaltrials.gov/ct2/show/NCT05411094">https://clinicaltrials.gov/ct2/show/NCT05411094</a>
10525	A Phase 1b Trial of ZEN-3694 with Pembrolizumab and Nab-Paclitaxel in Patients with Metastatic Triple-Negative Breast Cancer	ETCTN-wide	No	Breast	<a href="https://clinicaltrials.gov/ct2/show/NCT05422794">https://clinicaltrials.gov/ct2/show/NCT05422794</a>
10487	A Phase II Study of Lutetium Lu 177 Dotatate in Metastatic Prostate Cancer with Neuroendocrine Differentiation	ETCTN-wide	No	Genitourinary, Endocrine	<a href="https://clinicaltrials.gov/ct2/show/NCT05691465">https://clinicaltrials.gov/ct2/show/NCT05691465</a>
10500	Phase 1/Expansion study of tazemetostat plus belinostat for the treatment of relapsed or refractory lymphoma	ETCTN-wide	No	Lymphoma	<a href="https://clinicaltrials.gov/ct2/show/NCT05627245">https://clinicaltrials.gov/ct2/show/NCT05627245</a>
10528	Phase 1 study of the POLq inhibitor Novobiocin in BRCA-mutant and other DNA damage repair-deficient solid tumors	ETCTN-wide	No	ST Mutations	<a href="https://clinicaltrials.gov/ct2/show/NCT05687110">https://clinicaltrials.gov/ct2/show/NCT05687110</a>
10479	A Phase I Dose Escalation-Expansion Trial of Sunitinib Malate plus Lutetium Lu 177 Dotatate (Lutathera) in Somatostatin Receptor Positive Pancreatic Neuroendocrine Tumors	ETCTN-wide	No	Endocrine, Gastrointestinal	<a href="https://clinicaltrials.gov/ct2/show/NCT05687123">https://clinicaltrials.gov/ct2/show/NCT05687123</a>

**All ETCTN Trials: Updated June 9, 2025 (Includes trials that are in review, approved, and active)**

<b>CTEP Trial ID</b>	<b>Title</b>	<b>Limited/ETCTN-wide</b>	<b>Radiation Oncology</b>	<b>Disease Area(s)</b>	<b>ClinicalTrials.gov website (if available)</b>
10505	A Phase 1/2 Trial of Selinexor and Temozolomide in Recurrent Glioblastoma	ETCTN-wide	No	Brain	<a href="https://clinicaltrials.gov/ct2/show/NCT05432804">https://clinicaltrials.gov/ct2/show/NCT05432804</a>
10527	A Molecularly Driven Phase 1b Dose Escalation and Dose Expansion Study of the DNA-PK Inhibitor Peposertib (M3814) in Combination with the ATR Inhibitor M1774	ETCTN-wide	No	ST Mutations	<a href="https://clinicaltrials.gov/ct2/show/NCT05687136">https://clinicaltrials.gov/ct2/show/NCT05687136</a>
10522	A Phase I Clinical Trial of CA-4948 in Combination with Gemcitabine and Nab-Paclitaxel in Metastatic or Unresectable Pancreatic Ductal Carcinoma	ETCTN-wide	No	Gastrointestinal	<a href="https://clinicaltrials.gov/ct2/show/NCT05685602">https://clinicaltrials.gov/ct2/show/NCT05685602</a>
10538	Venetoclax In Combination with ASTX727, an All-ORal Therapy for Chronic Myelomonocytic Leukemia and Other MDS/MPN with Excess Blasts (VICTORY-MDS/MPN): a Randomized, Phase 2 Trial	ETCTN-wide	No	Leukemia	<a href="https://clinicaltrials.gov/ct2/show/NCT05600894">https://clinicaltrials.gov/ct2/show/NCT05600894</a>
10546	Targeting DNA Methyltransferases in Metastatic Triple-Negative Breast Cancer	ETCTN-wide	No	Breast	<a href="https://clinicaltrials.gov/ct2/show/NCT05673200">https://clinicaltrials.gov/ct2/show/NCT05673200</a>
10553	A Phase II Clinical and Biomarker Study of Darolutamide in Combination with Androgen Deprivation Therapy (ADT) for Hormone-Therapy Naïve Recurrent and/or Metastatic Androgen Receptor (AR) Positive Salivary Gland Cancer Patients	ETCTN-wide	No	Head and Neck	<a href="https://clinicaltrials.gov/ct2/show/NCT05669664">https://clinicaltrials.gov/ct2/show/NCT05669664</a>

**All ETCTN Trials: Updated June 9, 2025 (Includes trials that are in review, approved, and active)**

<b>CTEP Trial ID</b>	<b>Title</b>	<b>Limited/ETCTN-wide</b>	<b>Radiation Oncology</b>	<b>Disease Area(s)</b>	<b>ClinicalTrials.gov website (if available)</b>
10558	A phase II randomized control trial of triapine plus lutetium 177 dotatate versus lutetium 177 dotatate alone for well-differentiated somatostatin receptor-positive neuroendocrine tumors	ETCTN-wide	No	Endocrine	<a href="https://clinicaltrials.gov/ct2/show/NCT05724108">https://clinicaltrials.gov/ct2/show/NCT05724108</a>
10561	Rapid Analysis and Response Evaluation of Combination Anti-neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 3 Tiragolumab + Atezolizumab	Limited	No	Solid Tumors, NOS	<a href="https://clinicaltrials.gov/ct2/show/NCT05715281">https://clinicaltrials.gov/ct2/show/NCT05715281</a>
10563	A phase 1 study of peposertib (M3814) and low-dose liposomal doxorubicin (Doxil®) in patients with metastatic leiomyosarcoma and other soft tissue sarcomas	ETCTN-wide	No	Sarcoma	<a href="https://clinicaltrials.gov/ct2/show/NCT05711615">https://clinicaltrials.gov/ct2/show/NCT05711615</a>
10597	A Phase 1 trial of APG-1252 (pelcitoclax) and cobimetinib in recurrent ovarian and endometrial cancers	ETCTN-wide	No	Gynecologic	<a href="https://clinicaltrials.gov/ct2/show/NCT05691504">https://clinicaltrials.gov/ct2/show/NCT05691504</a>
10577	Pilot Study of CBX-12 Pharmacodynamics in Patients with Advanced Solid Tumors	Limited	No	Solid tumor (no specified mutations)	<a href="https://clinicaltrials.gov/ct2/show/NCT05691517">https://clinicaltrials.gov/ct2/show/NCT05691517</a>
10572	A Phase 1 Trial Evaluating the Combination of Temozolomide and the Ataxia Telangiectasia and Rad3-Related Inhibitor M1774	Limited	No	ST Mutations	<a href="https://clinicaltrials.gov/ct2/show/NCT05691491">https://clinicaltrials.gov/ct2/show/NCT05691491</a>
10590	A Phase 2 Study of Mosunetuzumab or Rituximab in Nodular Lymphocyte-Predominant Hodgkin Lymphoma	ETCTN-wide	No	Lymphoma	<a href="https://clinicaltrials.gov/ct2/show/NCT05886036">https://clinicaltrials.gov/ct2/show/NCT05886036</a>

**All ETCTN Trials: Updated June 9, 2025 (Includes trials that are in review, approved, and active)**

<b>CTEP Trial ID</b>	<b>Title</b>	<b>Limited/ETCTN-wide</b>	<b>Radiation Oncology</b>	<b>Disease Area(s)</b>	<b>ClinicalTrials.gov website (if available)</b>
10596	A Phase 1b Study of Menin Inhibitor SNDX-5613 in Combination with Daunorubicin and Cytarabine in Newly Diagnosed Patients with Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL Rearranged Disease	ETCTN-wide	No	Leukemia	<a href="https://clinicaltrials.gov/ct2/show/NCT05886049">https://clinicaltrials.gov/ct2/show/NCT05886049</a>
10579	Phase I Trial of ZEN003694 (ZEN-3694) in Combination with Capecitabine in Patients with Solid Tumors	Limited	No	Solid tumors (dose escalation), GI	<a href="https://clinicaltrials.gov/ct2/show/NCT05803382">https://clinicaltrials.gov/ct2/show/NCT05803382</a>
10601	A Phase 1 Study of Mosunetuzumab with Polatuzumab Vedotin and Lenalidomide (M+Pola+Len) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)	ETCTN-wide	No	Lymphoma	<a href="https://clinicaltrials.gov/study/NCT06015880">https://clinicaltrials.gov/study/NCT06015880</a>
10559	A Phase 2 Study of Erdafitinib in Patients with Recurrent or Progressive IDH-Wild Type Glioma with FGFR-TACC Gene Fusion	ETCTN-wide	No	Brain	<a href="https://clinicaltrials.gov/ct2/show/NCT05859334">https://clinicaltrials.gov/ct2/show/NCT05859334</a>
10603	Phase II Study of M1774 in Refractory SPOP-Mutant Prostate Cancer	ETCTN-wide	No	Genitourinary	<a href="https://clinicaltrials.gov/ct2/show/NCT05828082">https://clinicaltrials.gov/ct2/show/NCT05828082</a>
10592	A Phase 2 Study of ATR Inhibition in Advanced PD-(L)1-Refractory Merkel Cell Carcinoma	ETCTN-wide	No	Skin and other melanoma	<a href="https://clinicaltrials.gov/study/NCT05947500">https://clinicaltrials.gov/study/NCT05947500</a>
10614	A Phase 1/2 Study of Nivolumab and Ipilimumab in Combination with Sirolimus and Prednisone in Kidney Transplant Recipients with Selected Unresectable or Metastatic Cutaneous Cancers	ETCTN-wide	No	Skin and other melanoma	<a href="https://clinicaltrials.gov/ct2/show/NCT05896839">https://clinicaltrials.gov/ct2/show/NCT05896839</a>

**All ETCTN Trials: Updated June 9, 2025 (Includes trials that are in review, approved, and active)**

<b>CTEP Trial ID</b>	<b>Title</b>	<b>Limited/ETCTN-wide</b>	<b>Radiation Oncology</b>	<b>Disease Area(s)</b>	<b>ClinicalTrials.gov website (if available)</b>
10605	Phase I Trial of ZEN-3694 in Combination with Cetuximab and Encorafenib in Patients with Refractory BRAF V600E Metastatic Colorectal Cancer	ETCTN-wide	No	Gastrointestinal	<a href="https://clinicaltrials.gov/study/NCT06102902">https://clinicaltrials.gov/study/NCT06102902</a>
10608	A Phase II Trial of Durvalumab with Gemcitabine and Cisplatin as Neoadjuvant Therapy for High-Risk Resectable Intrahepatic Cholangiocarcinoma	ETCTN-wide	No	Gastrointestinal	<a href="https://clinicaltrials.gov/study/NCT06050252">https://clinicaltrials.gov/study/NCT06050252</a>
10612	A Randomized Phase 2 Study of Daratumumab-Selinexor-Velcade-Dexamethasone (Dara-SVD) for High-Risk Newly Diagnosed Multiple Myeloma	ETCTN-wide	No	Myeloma	<a href="https://clinicaltrials.gov/study/NCT06169215">https://clinicaltrials.gov/study/NCT06169215</a>
10629	A Phase I Dose Finding and Phase II Randomized Trial of Iadademstat Combined with Immune Checkpoint Inhibition Maintenance After Initial Chemoimmunotherapy in Patients with Extensive-Stage Small Cell Lung Cancer	ETCTN-wide	No	Lung	<a href="https://clinicaltrials.gov/study/NCT06287775">https://clinicaltrials.gov/study/NCT06287775</a>
10653	A phase I study of Lintuzumab-Ac-225 in combination with venetoclax and ASTX-727 in adults with newly diagnosed AML	ETCTN-wide	No	Leukemia	<a href="https://clinicaltrials.gov/study/NCT06802523">https://clinicaltrials.gov/study/NCT06802523</a>
10637	Phase 2 Trial of Venetoclax in Classic or Variant Hairy Cell Leukemia	Limited	No	Leukemia	<a href="https://clinicaltrials.gov/study/NCT06311227">https://clinicaltrials.gov/study/NCT06311227</a>

**All ETCTN Trials: Updated June 9, 2025 (Includes trials that are in review, approved, and active)**

<b>CTEP Trial ID</b>	<b>Title</b>	<b>Limited/ETCTN-wide</b>	<b>Radiation Oncology</b>	<b>Disease Area(s)</b>	<b>ClinicalTrials.gov website (if available)</b>
10554	Phase 1 Study of Trastuzumab Deruxtecan (DS-8201a) in Combination with Azenosertib (ZN-c3) in HER2-Expressing/Amplified Cyclin E-Amplified Gastric/Gastroesophageal Junction Cancer and Other Solid Tumors with HER2 Expression	Limited for escalation ; wide for expansion	No	Gastrointestinal; Solid tumors (dose escalation)	<a href="https://clinicaltrials.gov/study/NCT06364410">https://clinicaltrials.gov/study/NCT06364410</a>
10630	Phase 1 Trial of Iadademstat in Combination with Venetoclax and Azacitidine in Patients with Treatment Naïve AML	ETCTN-wide	No	Leukemia	<a href="https://clinicaltrials.gov/study/NCT06514261">https://clinicaltrials.gov/study/NCT06514261</a>
10636	Phase 1 Trial of CA-4948 in Combination with Pembrolizumab to Overcome Resistance to PD-1/PD-L1 Blockade in Metastatic Urothelial Cancer	ETCTN-wide	No	Genitourinary	<a href="https://clinicaltrials.gov/study/NCT06439836">https://clinicaltrials.gov/study/NCT06439836</a>
10657	Phase I/II Study to Evaluate the Feasibility and Efficacy of Sequential Abemaciclib and Gemcitabine Treatment in Patients with Retinoblastoma (Rb)+ Sarcomas	Limited	No	Sarcoma	<a href="https://clinicaltrials.gov/study/NCT06498648">https://clinicaltrials.gov/study/NCT06498648</a>
10674	A phase I study evaluating the safety of Cirtuvivint as monotherapy and in combination with ASTX727 and ASTX727 + venetoclax in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)	Limited	No	Leukemia	<a href="https://clinicaltrials.gov/study/NCT06484062">https://clinicaltrials.gov/study/NCT06484062</a>
10620	A Phase 1b Trial of Teclistamab in Combination with Iberdomide for Relapsed/Refractory Multiple Myeloma	ETCTN-wide	No	Myeloma	<a href="https://clinicaltrials.gov/study/NCT06465316">https://clinicaltrials.gov/study/NCT06465316</a>

**All ETCTN Trials: Updated June 9, 2025 (Includes trials that are in review, approved, and active)**

<b>CTEP Trial ID</b>	<b>Title</b>	<b>Limited/ETCTN-wide</b>	<b>Radiation Oncology</b>	<b>Disease Area(s)</b>	<b>ClinicalTrials.gov website (if available)</b>
10655	Phase I Clinical Trial of CA-4948 in Combination with FOLFOX Plus Bevacizumab as Frontline Treatment in Patients with Metastatic Colorectal Cancer	ETCTN-wide	No	Gastrointestinal	<a href="https://clinicaltrials.gov/study/NCT06696768">https://clinicaltrials.gov/study/NCT06696768</a>
10675	A Randomized Phase II Trial of ASTX727 +/- Iadademstat in Accelerated/Blast-Phase Philadelphia Chromosome-Negative Myeloproliferative Neoplasms (MPNs)	ETCTN-wide	No	Leukemia	<a href="https://clinicaltrials.gov/study/NCT06661915">https://clinicaltrials.gov/study/NCT06661915</a>
10664	Phase 1b Study of Combination Tovorafenib and Rituximab Treatment in Relapsed or Refractory Classical Hairy Cell Leukemia and Phase 2 Randomized Study Comparing Tovorafenib and Rituximab with Cladribine and Rituximab for Front-Line Treatment of Classical Hairy Cell Leukemia	ETCTN-wide	No	Leukemia, Lymphoma	<a href="https://clinicaltrials.gov/study/NCT06965114">https://clinicaltrials.gov/study/NCT06965114</a>
10667	Pilot Study of Pidnarulex Pharmacodynamics in Patients with Advanced Solid Tumors	ETCTN-limited	No	Solid tumor (no specified mutations)	<a href="https://clinicaltrials.gov/study/NCT06606990">https://clinicaltrials.gov/study/NCT06606990</a>
10670	Phase 1 study of 5-fluorouracil in combination with abemaciclib in metastatic, refractory CRC	ETCTN-wide	No	Gastrointestinal	<a href="https://clinicaltrials.gov/study/NCT06654037">https://clinicaltrials.gov/study/NCT06654037</a>

**All ETCTN Trials: Updated June 9, 2025 (Includes trials that are in review, approved, and active)**

<b>CTEP Trial ID</b>	<b>Title</b>	<b>Limited/ETCTN-wide</b>	<b>Radiation Oncology</b>	<b>Disease Area(s)</b>	<b>ClinicalTrials.gov website (if available)</b>
10660	Histologically or cytologically documented locally advanced or metastatic KRASG12C-mutant non-small cell lung cancer (NSCLC) that has previously been treated with a KRASG12C inhibitor AND an immune checkpoint inhibitor (ICI) and/or chemotherapy, either given concurrently or sequentially.	ETCTN-wide	No	Lung	Not available currently.
10699	A Phase I Trial Combining Triapine with Radiation Therapy for Recurrent Glioblastoma	ETCTN-wide	No	Brain	<a href="https://clinicaltrials.gov/study/NCT06860594">https://clinicaltrials.gov/study/NCT06860594</a>
10666	A Dose-Finding Phase I Study of Bone-targeted Stannic-117m Pentatate (Sn-117m-DTPA) in Solid Tumors with Skeletal Metastases	ETCTN-wide	No	Solid Tumors, NOS	Not available currently.
10703	A Phase I/II Trial of Sapanisertib in Combination with Cabozantinib in $\beta$ -Catenin-Mutated Hepatocellular Carcinoma	Limited for escalation ; wide for Phase II	No	Gastrointestinal	<a href="https://clinicaltrials.gov/study/NCT06811116">https://clinicaltrials.gov/study/NCT06811116</a>
10707	Phase 2 Trial of CBX-12 for Metastatic Chemotherapy-Refractory Microsatellite Stable Colorectal Cancer	ETCTN-wide	No	Gastrointestinal	<a href="https://clinicaltrials.gov/study/NCT06730100">https://clinicaltrials.gov/study/NCT06730100</a>
10695	Lintuzumab-Ac225 monotherapy for patients with hypomethylating agent-refractory myelodysplastic syndrome	ETCTN-wide	No	Leukemia	<a href="https://clinicaltrials.gov/study/NCT06888323">https://clinicaltrials.gov/study/NCT06888323</a>
10702	A Phase II Study of Glofitamab for Relapsed/Refractory Mantle Cell Lymphoma in Patients Previously Treated with CD19-Directed CAR T-Cell Therapy	ETCTN-wide	No	Lymphoma	<a href="https://clinicaltrials.gov/study/NCT07003295">https://clinicaltrials.gov/study/NCT07003295</a>

**All ETCTN Trials: Updated June 9, 2025 (Includes trials that are in review, approved, and active)**

<b>CTEP Trial ID</b>	<b>Title</b>	<b>Limited/ETCTN-wide</b>	<b>Radiation Oncology</b>	<b>Disease Area(s)</b>	<b>ClinicalTrials.gov website (if available)</b>
10706	A Phase 2 Window of Opportunity Trial of Neoadjuvant Agonistic Anti-CD40 Antibody CDX-1140 and Cemiplimab in AJCC Stage III-IV Head and Neck Cancer Patients Prior to Surgery	ETCTN-wide	No	Head and Neck	<a href="https://clinicaltrials.gov/study/NCT06980038">https://clinicaltrials.gov/study/NCT06980038</a>
10708	A Phase 2 Pilot Study of Mirdametinib in Relapsed Refractory Chronic Lymphocytic Leukemia	ETCTN-wide	No	Leukemia	Not available currently.
10713	A Phase I Trial of 225Ac-anti-CD33 and PD1-Inhibitor in Recurrent Glioblastoma	Limited	No	Brain	Not available currently.
10717	Phase 1b/2 Trial of Pidnarulex in MYC Aberrant Lymphoma	ETCTN-wide	No	Lymphoma	Not available currently.
10727	Phase 1b study of teclistamab in relapsed/refractory plasmablastic lymphoma	ETCTN-wide	No	Lymphoma	Not available currently.
10716	A Phase 1 and Randomized Phase 2 Trial of CX-5461 (Pidnarulex) and Cemiplimab (REGN2810) in Refractory Microsatellite Stable Colorectal Cancer	ETCTN-wide	No	Gastrointestinal	Not available currently.
10720	Phase 1b Study of Pidnarulex and Trastuzumab Deruxtecan in Patients with HER2 Expressing Solid Tumors	ETCTN-wide	No	Breast, Solid tumors (mutations)	Not available currently.
10721	Phase II Trial of Neoadjuvant Chemoimmunotherapy vs Chemotherapy in Sinonasal Squamous Cell Carcinoma	Limited	No	Head and Neck	Not available currently.

All ETCTN Trials: Updated June 9, 2025 (Includes trials that are in review, approved, and active)

CTEP Trial ID	Title	Limited/ ETCTN- wide	Radiation Oncology	Disease Area(s)	ClinicalTrials.gov website (if available)
10732	Phase I trial of ATR inhibitor camonsertib combined with stereotactic body radiation therapy for recurrent head and neck squamous cell carcinoma	Limited	No	Head and Neck	Not available currently.